Research programme: respiratory syncytial virus vaccine - ID Biomedical
Alternative Names: Respiratory syncytial virus vaccine research programme - ID BiomedicalLatest Information Update: 18 Apr 2011
At a glance
- Originator ID Biomedical Corporation
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Respiratory syncytial virus infections
Most Recent Events
- 08 Dec 2005 ID Biomedical Corporation has been acquired by GlaxoSmithKline
- 25 Jun 2003 Preclinical trials in Respiratory syncytial virus infections in Canada (Intranasal)